Breakthrough: Pembrolizumab Approved for Advanced Cervical Cancer Treatment
Merck Sharp & Dohme (Merck’s trade name) announced that its PD-1 inhibitor pembrolizumab (trade name: Koraida®) has been approved by the China National Drug Administration (NMPA) for the treatment of patients with the International Federation…